Nuzenio

Myelofibrosis The Manila

Myelofibrosis The Manila entity intelligence is not indexable yet because Nuzenio needs more live source-attributed coverage.

topic 3 latest news signals 1 publisher sources 100/100 entity strength

Latest news

Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis - The Manila TimesThe Manila Times · Wed, 05 Aug 2026 12:19:47 GMTDamora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila TimesThe Manila Times · Mon, 03 Aug 2026 20:10:08 GMTKeros Therapeutics to Receive Development Milestone Payment from Partner Takeda - The Manila TimesThe Manila Times · Fri, 31 Jul 2026 07:00:00 GMT

Timeline

Wed, 05 Aug 2026 12:19:47 GMTDamora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis - The Manila Times
Mon, 03 Aug 2026 20:10:08 GMTDamora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fri, 31 Jul 2026 07:00:00 GMTKeros Therapeutics to Receive Development Milestone Payment from Partner Takeda - The Manila Times

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Myelofibrosis The Manila.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

1 distinct publisher/source names are currently connected to this entity page.